c-Jun (cellular Jun) is a transcription factor activated by phosphorylation by the stress activated protein kinase/c-Jun-N-terminalkinase pathway in response to extracellular signals and cytokines. We show that adenovirus mediated gene transfer of dn-cJun (dominant negative form of c-Jun) in C57BL/6 mice increased greatly apoE (apolipoprotein E) hepatic mRNA and plasma levels, increased plasma cholesterol, triglyceride and VLDL (very low density lipoprotein) levels and resulted in the accumulation of discoidal HDL (high density lipoprotein). A similar but more severe phenotype was generated by overexpression of the mouse apoE in C57BL/6 mice, suggesting that dyslipidemia induced by dn-cJun was the result of apoE overexpression.
Unexpectedly, infection of apoE -/-mice with adenovirus expressing dn-c-Jun reduced by 70% plasma cholesterol, suggesting that dn-c-Jun affected other genes that control plasma cholesterol levels. To identify these genes we performed whole genome expression analysis (34, Cellular Jun (c-Jun) is a 39-kDa inducible transcriptional factor that forms homo-or hetero-dimers with other activating protein-1 (AP-1) family members and regulates the transcription of target genes that contain AP-1 elements (5′-TGAC/GTCA-3′)in their promoters (1) (2) (3) (4) . c-Jun is a modular protein that consists of a C-terminal dimerization domain (1;5;6), a DNA-binding domain and an N-terminal transactivation domain (2;7-12) . The transcriptional activity of c-Jun is triggered by phosphorylation of serines 63 and 73 by the cJun N-terminal kinase (JNK) (13) (14) (15) (16) (17) (18) which in turn is activated in response to inflammatory cytokines such as tumor necrosis factor-α (TNFα) and interleukin (IL-1) and cellular stress signals (19) .
JNK and c-Jun as well as signals that activate them have been linked to the regulation of genes involved in lipid and lipoprotein homeostasis and in atherosclerosis (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) . Previous in vitro studies have shown that c-Jun and viral Jun (vJun) repressed the human apolipoprotein CIII (apoCIII) (25) and the chicken apolipoprotein A-I (apoA-I) (24) promoter activity respectively. In addition, inhibition of JNK1 increased the apoA-I promoter activity (21) . The JNK signaling pathway has also been shown to affect the expression of sterol-regulatory element binding protein-1, which in turn activates stearoyl coenzyme A desaturase-1 (Scd-1) and fatty acid synthetase that are involved in lipogenesis (32) .
Scd is a 40-kDa microsomal membrane protein that catalyzes the introduction of the first cis-double bond in the ∆9 position in several fatty acyl-CoA substrates, preferably palmitoyland stearoyl-CoA and has four isoforms (33) (34) (35) (36) (37) . The hepatic isoform Scd-1 is induced by restriction of dietary fat (38) . In mice with a naturally occurring Scd-1 deficiency and in Scd-1 knockout mice VLDL secretion, as well as cholesterol and triglyceride synthesis are impaired (39;40) .
To study the effect of c-Jun on the apolipoprotein gene expression and lipid and lipoprotein homeostasis we used adenovirus mediated gene transfer of a dominant negative mutant of c-Jun that lacks aa 3-122 of the transactivation domain (Ad-dn-c-Jun) (41;42) in HepG2 cells, C57BL/6 mice and apoE -/-mice. This treatment increased dramatically apolipoprotein E (apoE) mRNA in HepG2 cells, as well as the hepatic apoE mRNA levels, plasma apoE, cholesterol and triglyceride levels in C57BL/6 mice. The induction of dyslipidemia could be accounted for by the increase in plasma apoE levels. A similar treatment of apoE -/-mice decreased their plasma cholesterol levels. Whole genome microarray analysis of hepatic RNA of apoE -/-mice treated with Ad-dn-c-Jun along with Northern blotting and gene transfer studies implicated Scd-1 in the reduction of dyslipidemia that is induced by dn-c-Jun.
Experimental Procedures
Materials. Reagents were purchased from the following commercial sources. Restriction enzymes and modifying enzymes (T4 DNA ligase, Klenow fragment of DNA polymerase I) were purchased from New England Biolabs. Cell culture reagents (Dulbecco's modification of eagle's medium, fetal bovine serum, trypsinethylene diamine tetraacetic acid and phosphate buffered saline) were from Invitrogen, Inc. TRIzol reagent was purchased from Invitrogen, Inc. Proteinase inhibitors mixture was purchased from Sigma. Antibodies were purchased from Santa Cruz Biotechnology, Inc. cDNAs were purchased from American Type Culture Collection (ATCC). Radioactive α-32P-deoxycytidine triphosphate and α-32P-deoxyguanosine triphosphate were purchased from Perkin Elmer, whereas deoxy-adenosine triphosphate and deoxy-thymidine triphosphate were purchased from GE Healthcare.
Construction of Recombinant Adenoviruses -The plasmid that contained the cDNA of the dominant negative form of human c-Jun (pcDNA3.1-dn-c-Jun, ∆3-122) was kindly provided by M. J. Birrer (NCI, NIH, Bethesda USA). The cDNA was cloned into NotI and HindIII restriction sites of the pAdTrackCMV vector. The plasmid containing the rat Scd-1 cDNA (pGEM-11Zf(+)-Scd-1) was a generous gift from J. Ozols (University of Connecticut Health Center). The Scd-1 cDNA was subcloned in EcoRI and NotI sites of the pcDNA3.1 vector and subsequently cloned in KpnI and XbaI sites of the pAdTrackCMV vector. The plasmid that contained the cDNA of the human wild-type (WT) c-Jun (pOTB7-c-Jun) was purchased from ATCC. The c-Jun cDNA was subcloned in EcoRI and XhoI sites of the pcDNA3.1 vector. The PacI site of this vector that was present in the 5΄ UTR of the c-Jun cDNA, was destroyed following PacI digestion of the pcDNA3.1-c-Jun and treatment with T4 polynucleotide kinase and religation. The c-Jun cDNA insert was excised from the pcDNA 3.1 vector with KpnI and XhoI digestion and cloned in corresponding sites of the pAdTrackCMV vector. The recombinant adenoviruses were constructed as described (43) using the Ad-Easy-1 system where the adenovirus construct is generated in bacteria BJ-5183 cells (44) . Correct clones were propagated in RecA DH5α cells. The recombinant adenoviral vectors were linearized with PacI and used to infect 911 cells (45) . Following large scale infection of human embryonic kidney 293 cell cultures, the recombinant adenoviruses were purified by two consecutive Cesium Chloride ultracentrifugation steps, dialyzed, and titrated (46) . Usually, titers of ~2-7 x 10 10 plaque forming units (pfu)/ml were obtained. The adenovirus that expresses the wild-type mouse apoE (Ad-mapoE) was kindly provided by K.W. van Dijk (Leiden University, Netherlands).
RNA Purification and Analysis -To assess the gene expression following adenovirus mediated gene transfer at least 5 mice from each group were sacrificed 4 days post-infection. Livers that were collected from individual animals, were frozen in liquid nitrogen, and stored at -80°C. Total RNA was purified from livers using the TRIzol reagents according to the instructions of the manufacturer and analyzed for expression of dn-c-Jun, c-Jun, apoE and Scd-1 genes by Northern blotting and quantitated by phosphorimaging (46) . Total RNA was isolated similarly from HepG2 cells using the TRIzol reagents and analyzed by Northern blotting (14) .
Cell Culture Studies and Protein AnalysisHuman HepG2 cells (human hepatoma) were grown to confluence in medium containing 10% fetal bovine serum. The medium was changed to 2% Heat Inactivated Horse serum and the cells were infected in at least duplicates with control adenovirus that expresses the Green Fluorescent Protein (Ad-GFP) and the adenoviruses expressing the dn-c-Jun form (Ad-dn-c-Jun) and the wild type Scd-1 (Ad-Scd-1) at a multiplicity of infection (MOI) of 5. Twenty-four-hours post-infection, cells were washed twice with phosphate-buffered saline, and fresh 10% fetal bovine serum containing medium was added. To assess protein expression 48 h post incubation, cell lysates were collected and analyzed by Western Blotting for protein expression.
Animal Studies -C57BL/6 and apoE -/-mice 8-12 weeks-old were used in these studies. Groups of 5-10 mice were infected intravenously through the tail vein with adenoviruses of dose of 2x10 9 pfu. Blood was obtained from the tail vein after a 4-h fasting period prior to adenoviral infection and 3 and 4 days post-infection. Aliquots of plasma were stored at 4 and -20 °C.
RNA Purification and Analysis -To assess the gene expression following adenovirus mediated gene transfer at least 5 mice from each group were sacrificed 4 days post-infection. Livers were collected from individual animals, were frozen in liquid nitrogen and stored at -80°C. Total RNA was purified from livers using the TRIzol reagents according to the instructions of the manufacturer. Purified RNA was analyzed for expression of dn-c-Jun, apoE and Scd-1 genes by Northern blotting and quantitated by phosphorimaging (46) . Total RNA was isolated similarly from HepG2 cells using the TRIzol reagents and analyzed by Northern blotting (14) .
Fast Performance Liquid Chromatography (FPLC) Analysis and Lipid Determination -For FPLC analysis of serum samples, 12 µl of serum were diluted 1:5 with phosphate-buffered saline, and loaded onto a Superose 6 column in a SMART micro FPLC system (Amersham Biosciences), and eluted with phosphatebuffered saline. A total of 25 fractions of 50 µl volume each were collected for further analysis. Triglycerides and cholesterol were determined using the GPO-Trinder Kit (Sigma) and CHOL-MPR3 kit (Roche Applied Science), according to the manufacturer's instructions. The triglyceride and cholesterol concentrations of the serum and the FPLC fractions were determined spectrophotometrically at 540 and 492 nm respectively, as described previously (43) .
Rate of VLDL Triglyceride Production in C57/BL6 Mice Infected with Ad-dn-c-Jun -VLDL triglyceride secretion was determined following infection of C57BL6 mice with 2x10 9 pfu of adenoviruses expressing either Ad-dn-cJun or the control Ad-GFP adenovirus. Four days postinfection, mice were fasted for 4 h and then injected with Triton WR-1339 at a dose of 500 mg/kg of body weight, using a 15% solution (w/v) in 0.9% NaCl (Triton WR-1339 has been shown to completely inhibit VLDL catabolism (47) . Serum samples were isolated 20, 40, 60, and 90 min after injection with Triton WR-1339. Serum triglycerides were measured, and the rate of VLDL-triglyceride secretion expressed in mg/dl/min was determined as described previously (43) .
Statistical Analysis -Data are presented as the mean ± Standard Error. Comparison of data from two groups of mice was performed using the paired-two-sample-for-means t test with unequal variance.
Density Gradient Ultracentrifugation -To assess the protein composition of plasma 0.3 ml of serum from mice infected either with the control Ad-GFP, Ad-dn-c-Jun or Ad-mapoE were brought to a volume of 0.5 ml with phosphate-buffered saline and adjusted to a density of 1.23 g/ml with KBr. This solution was then overlaid with 1 ml of 1.21 g/ml KBr, 2.5 ml of 1.063 g/ml KBr, 0.5 of 1.019 g/ml KBr, and 0.5 ml of saline. The mixture was centrifuged for 22 h in a SW-41 rotor at 34,000 rpm. Following ultracentrifugation, 10 fractions of 0.5 ml were collected and analyzed by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).
Electron Microscopy (EM) -Aliquots of the fractions from equilibrium density gradient centrifugation after dialysis against ammonium acetate and carbonate buffer were stained with sodium phosphotungstate, visualized in the Phillips CM-120 electron microscope (Phillips Electron Optics, Eindhoven, Netherlands), and photographed as described previously (48) . The photomicrographs were taken at x75,000 magnification and enlarged three times.
Target Preparation, Microarray Hybridization and Quality Assessment -Total RNA was extracted from the livers of ten apoE -/-mice. Five of these mice were infected with Addn-c-Jun and five were infected with a control adenovirus expressing GFP. Each liver specimen was homogenized in TRIzol (Life Technologies, Rockville, MD) and choloroform/isoamyl alcohol (49:1). All RNA samples used for microarray analysis were carefully evaluated to have a 28S/18S rRNA ratio close to 2 on 1.5% agarose gels, and absorbance ratios 260nm/280nm between 1.9 and 2.1. A quantity of 6-8 µg of targets from each RNA sample were prepared as previously described (49) and hybridized to GeneChip Whole Mouse Genome 430 2.0 Arrays (Affymetrix). The 45,000 probe sets on these arrays analyze the expression levels of over 39,000 transcripts and variants from over 34,000 well-characterized mouse genes. The arrays were washed and stained by the Affymetrix 450 Fluidics station, and scanned using the GeneChip Scanner 3000, enabled for High-Resolution Scanning. The expression level and a "present", "absent", or "marginal" call was assigned to each probe set by the GeneChip Operating Software v1.4 (Affymetrix).
The number of probe sets called "present" by the software for each specimen was 44%-49%, indicating that these transcripts were present at sufficient levels for accurate quantitation. Target quality was controlled for by ensuring the ratio of expression of the representative 3′ and 5′ sequences of the control genes beta-actin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) on the microarrays, was <3 in all ten data sets. The good hybridization quality was also established through a concentration gradient of spike-in Bacillus subtiliis transcripts which, as desired, gave a "present" call and increasing expression levels in all data sets.
Analysis of Raw Microarray DataHierarchical clustering was performed on unnormalized/unfiltered data, as described before (50) , using the Cluster and TreeView Software (51) with centered linear correlation as a measure of similarity using average linkage. A range of standard deviation thresholds were applied.
Following the initial processing step by the GeneChip Operating Software v1.4, the data were normalized as previously described (52) . This normalization corrects any uniform linear aberrations of the reported signals between any two replicate measurements which may arise from idiosyncrasies in the sample preparation, hybridization or scanning protocol. The data were then filtered to keep only probe sets with reliable expression measurements. This was defined as more than 3 "present" and 1 "marginal" calls per probe set in the ten datasets. Approximately 22,500 probe sets passed the filtering criteria.
Significant analysis of microarrays was used to identify significant gene expression changes between the two groups of mice (53) . A twoclass unpaired data analysis was performed on normalized and filtered data, using a ∆ threshold of 1.571 [the "∆" parameter enables the user to examine the effect of the false-positive rate in determining significance] and a fold threshold of 2 [where "fold" is calculated as the ratio of the average expression in dn-c-Jun infected apoE -/-mice versus control mouse datasets]. This resulted in the selection of probe sets with less than 2% median false discovery rate (FDR).
Results

Adenovirus-mediated gene transfer of a dominant negative form of c-Jun in C57BL/6
mice increases the hepatic mRNA and plasma apoE levels. The increase of plasma apoE in mice was associated with dyslipidemia and accumulation of discoidal HDL -We used adenovirus mediated gene transfer of dn-c-Jun in C57BL/6 mice in order to assess its effects on genes involved in lipid and lipoprotein homeostasis. For these experiments C57BL/6 mice were infected with 1-2x10 9 pfu of the adenovirus expressing the dn-c-Jun or the control adenovirus expressing GFP. Plasma was collected prior to infection as well as 3 and 4 days post-infection and hepatic RNA was extracted from liver obtained 4 days postinfection. This analysis showed efficient expression of the dn-c-Jun in the liver ( Figure  1A ) and a dramatic upregulation of hepatic apoE mRNA ( Figure 1B) . A similar upregulation of apoE mRNA levels was observed in HepG2 cells infected with the Ad-dn-c-Jun (Supplementary Figure 1) . Analysis of the cytoplasmic and nuclear extracts of infected HepG2 cells by SDS-PAGE and Western Blotting showed that the dn-c-Jun was expressed efficiently and was found both in cytoplasm and the nucleus (Supplementary Figure 2) . Fractionation of the plasma of C57BL/6 mice treated with the Ad-dn-c-Jun by density gradient ultracentrifugation and analysis of the fractions by SDS-PAGE showed that expression of dn-cJun in C57BL/6 mice increased dramatically plasma apoE levels as compared to the mice infected with the control adenovirus expressing GFP ( Figures 1C, D) .
Expression of dn-c-Jun increases the plasma cholesterol and triglycerides in C57BL/6 mice -
The treatment of C57BL/6 mice with the Ad-dnc-Jun increased 2.9-fold the plasma cholesterol levels and 5.8-fold the plasma triglyceride levels, as compared to the mice treated with the control adenovirus expressing GFP (Figure 2A,  B) . FPLC analysis of plasma from mice expressing the dn-c-Jun showed that the cholesterol and triglycerides were distributed predominantly in the Very Low Density Lipoprotein/Intermediate Density Lipoprotein/ Low Density Lipoprotein (VLDL/IDL/LDL) region ( Figure 2C,D) as compared to C57BL/6 mice infected with the control adenovirus expressing GFP where the cholesterol is distributed in the HDL region ( Figure 2C ). EM analysis of the fractions 5 to 8 corresponding to the HDL region ( Figure 1C, D) , that were obtained by density gradient ultracentrifugation showed that expression of dn-c-Jun in C57BL/6 mice was associated with the formation of discoidal HDL particles ( Figure 2F ) whereas the equivalent fractions 5-8 that were obtained from plasma of C57BL/6 mice infected with control adenovirus expressing the GFP formed spherical HDL particles ( Figure 2E ). The upregulation of the apoE gene and the induction of dyslipidemia is a unique feature of the dn-c-Jun. When C57BL/6 mice were infected with adenoviruses expressing WT cJun, the expression of the apoE gene was not affected and the plasma cholesterol and triglyceride levels remained normal 3 and 4 days post-infection (Supplementary Figure 3) . The rate of triglyceride secretion determined by Triton WR1339 injection 4 days post infection was increased 35% in C57BL/6 mice infected with adenovirus expressing dn-c-Jun as compared to mice infected with the control adenovirus expressing GFP (Supplementary Figure 4) . Previous studies indicated that apoE overexpression stimulates several fold VLDLtriglyceride (VLDL-TG) secretion (43;46;54-56) . Thus, the modest increase in VLDL-TG secretion promoted by the treatment of mice with Ad-dn-c-Jun suggests that other genes which may inhibit VLDL-TG secretion might be affected by dn-c-Jun.
Dyslipidemia induced by dn-c-Jun treatment can be accounted for by overexpression of mouse apoE (mapoE ) -To assess the contribution of mapoE to the dyslipidemia induced by the dn-c-Jun expression, C57BL/6 mice were infected with 2x10 9 pfu of adenovirus expressing mapoE or the control adenovirus expressing GFP and the plasma lipid and apoE levels, as well as the hepatic apoE mRNA levels were determined 4 days post infection. This analysis in the Ad-mapoE treated mice showed that the hepatic mapoE mRNA increased dramatically as compared to the endogenous mapoE mRNA levels ( Figure 3A ). Comparative analysis of apoE mRNA levels of mice infected with the adenoviruses expressing the dn-c-Jun or the mouse apoE showed that the levels of expression of apoE were comparable ( Figure  3B ). This increase in apoE mRNA following the infection with the adenovirus expressing the mouse apoE was accompanied by a dramatic increase in the plasma levels of mapoE (compare Figure 1D with Figure 3C ). The increase in plasma apoE was associated with 6.5-fold increase in plasma cholesterol and 7.8-fold increase in plasma triglycerides ( Figure 3D, E) Expression of dn-c-Jun in apoE -/-mice resulted in reduction of plasma lipid levels -To investigate whether dyslipidemia observed in Ad-dn-c-Jun infected mice was due to apoE overexpression, a similar analysis was undertaken in the apoE -/-mouse line which lacks endogenous apoE expression. apoE -/-mice were infected with 2x10 9 pfu with adenoviruses expressing either the dn-c-Jun or GFP. The expectation was that both treatments would not have any effect on the plasma lipid levels. Surprisingly, this analysis showed that the dn-cJun reduced by 70% the plasma cholesterol and triglyceride levels 3 or 4 days post-infection, as compared to the mice infected with the control adenovirus expressing GFP ( Figure 4A, B) . FPLC analysis of plasma showed that in mice treated with Ad-dn-c-Jun the VLDL cholesterol and triglyceride peaks were reduced 4 days postinfection as compared to that of apoE-deficient mice treated with Ad-GFP ( Figure 4C, D) .
Microarray analysis and Northern blotting of hepatic RNA obtained from apoE -/-mice that were treated with adenovirus expressing the dnc-Jun indicated downregulation of Scd-1 -
We used whole genome expression profiling to identify potential dn-c-Jun induced changes in the apoE -/-mouse liver. Hierarchical clustering of the microarray data revealed two distinct expression signatures. Specifically, the ten datasets were blindly grouped by the software in two distinct clusters, one containing the Ad-dnc-Jun treated and the other containing the control Ad-GFP treated apoE -/-mice ( Figure 5A ). The correlation coefficient values for intra-and intercluster comparisons ranged between 97%-99% and 95%-97% respectively.
In a second stage of bioinformatical analysis, we aimed at depicting the specific gene expression changes induced in Ad-dn-c-Jun infected apoE -/-mice using significant analysis of microarrays. After the application of stringent fold and false discovery rate thresholds, 123 probe sets were identified as significantly and highly changed. The majority of these probe sets were down-regulated and only two were upregulated (Supplementary Table 1 ). These probe sets represented proteins with a wide range of functional categories, a large proportion of which were metabolism (40%) and transport (~15%) related and fewer were defense response (10%) and cell cycle (~7%) related (Supplementary Figure 5) . Based on the Gene Ontology annotations, six probe sets represented 4 lipid metabolism related genes, namely apoE (+40-fold), macrophage inflammatory protein-2 (MIP2) (-2.6-fold), interleukin 1 receptor antagonist (Il1rn) (-2.45-fold) and stearoyl-CoAdesaturase-1 (Scd-1) (-3.27-fold) ( Figure 5A and Supplementary Table 1 submitted to Gene Expression Omnibus Database; provisional data series number: GSE6850). The decrease in Scd-1 mRNA was confirmed by Northern blotting analysis of hepatic total RNA extracted from livers of apoE -/-mice 4 days post-infection with adenoviruses expressing either the dn-c-Jun or GFP ( Figure 5B) . Constistent with the microarray data, quantitation of the Northern blot by phosphorimager showed that the Scd-1 mRNA levels of apoE -/-mice treated with dn-cJun decreased 3.6-fold. The inhibition of expression of Scd-1 is a unique feature of the dn-c-Jun and occurs both in the apoE -/-as well as C57BL/6 mice. Furthermore, Scd-1 expression is not affected by WT c-Jun in either C57BL/6 or apoE -/-mice (Supplementary Figure 6) . The increase in apoE mRNA of apoE -/-mice treated with the adenovirus expressing the dn-c-Jun is in agreement with the observed increase in apoE mRNA of C57BL/6 mice treated similarly with the adenovirus expressing the dn-c-Jun ( Figure  1B) . Figure 7) . To assess the potential role of Scd-1 downregulation in the reduction of the plasma cholesterol levels in apoE -/-mice following treatment with the adenovirus expressing the dn-c-Jun, we coinfected apoE -/-mice with 1x10 9 pfu of adenovirus expressing dn-c-Jun in combination with either 1x10 9 pfu of adenovirus expressing GFP or 1x10 9 pfu of adenovirus expressing Scd-1. Analysis of the hepatic mRNA levels of dn-cJun and Scd-1 and the plasma lipid levels 4 days post infection confirmed that expression of dn-cJun in combination with GFP ( Figure 6A ) decreased plasma cholesterol levels whereas simultaneous expression of dn-c-Jun and Scd-1 restored the high cholesterol levels of apoE -/-mice ( Figure 6B ). These treatments did not affect plasma triglyceride levels (data not shown).
The high cholesterol profile of apoE -/-mice is restored by simultaneous infection with adenoviruses expressing the dn-c-Jun and
Control experiments showed that adenovirus expressing Scd-1 did not affect plasma cholesterol and triglyceride levels (Supplementary Figure 8) . The findings suggest that plasma lipid levels are not affected by an increase in Scd-1 expression. Figure 7 is a schematic representation of the modulation of the cholesterol levels in C57BL/6 and apoE -/-mice following treatment with the adenovirus expressing the dn-c-Jun which will be discussed later.
Discussion
The correlation of JNK and c-Jun with lipid and lipoprotein metabolism and atherosclerosis led us to investigate the effects of a dominant negative form of c-Jun in the regulation of lipid levels in different mouse models.
The first important observation of our studies was that the dn-c-Jun caused dyslipidemia in C57BL/6 mice, which was characterized by increased plasma cholesterol and triglyceride levels that accumulated in the VLDL region. We were able to attribute the dyslipidemia observed in C57BL/6 mice to a dramatic increase in hepatic steady state apoE mRNA levels that resulted in increase in plasma apoE levels. The increase in apoE mRNA was documented by Northern blotting in C57BL/6 mice, as well as by whole genome microarray analysis in apoE -/-mice. The association of the high plasma apoE levels with the induction of dyslipidemia was supported by direct gene transfer of mouse apoE in C57BL/6 mice. This treatment produced a similar but more severe lipid and lipoprotein profile as that observed in C57BL/6 mice treated with the Ad-dn-c-Jun.
Furthermore, previous studies by us and others have shown that overexpression of human apoE does not correct the high cholesterol profiles of apoE -/-mice, does increase VLDLtriglyceride secretion and induces hypertriglyceridemia (43;46;54-56) . In humans and experimental animals plasma apoE levels correlate with plasma triglyceride levels (57;58). On the basis of this information we hypothesized that expression of dn-c-Jun in apoE -/-mice would not affect the plasma lipid levels. Surprisingly, however, the treatment of apoE -/-mice with adenovirus expressing the dn-c-Jun decreased their plasma cholesterol levels. To interpret this unexpected finding we performed whole genome microarray analysis of hepatic RNA obtained from Ad-dn-c-Jun treated and control (Ad-GFP treated) apoE -/-mice. Microarray data analysis with very strict thresholds (at least 2-fold changes and FDR less than 2%) identified 123 transcripts that were highly and significantly changed by the Ad-dnc-Jun treatment (Supplementary Table 1 ). The results were filtered for transcripts directly related to lipid and lipoprotein metabolism and atherosclerosis. Four transcripts emerged, namely MIP-2, IL-1rn, Scd-1 and apoE. The apoE transcript detected by microarrays represent the aberrant mouse apoE gene produced that also contains the neomycin mRNA (59) .
MIP-2 is a potent chemotactic agent for polymorphonuclear leukocytes that is secreted by macrophages. It was shown that MIP-2 was increased in the serum of apoE*3 Leiden mice fed a high fat diet that leads to dyslipidemia and atherosclerosis (60) . In this case the induction of MIP-2 appears to be the result of the dyslipidemia and the pro-inflammaotry conditions that are brought about by the high fat diet. MIP-2 also increases by treatment of macrophages with minimally modified LDL (61) . Thus, the observed downregulation of the MIP-2 gene by the dn-c-Jun in Kupffer cells may be the consequence rather than the cause of the reduction of plasma cholesterol and triglyceride levels of apoE -/-mice following treatment with dn-c-Jun.
IL-1rn is a protein that binds to IL-1 receptors and inhibits the binding of IL-1alpha and IL-1beta. IL-1rn is expressed in endothelial cells and is found in atherosclerotic lesions (62) . A polymorphism in intron 2 of the human IL-1rn gene, that reduces the plasma concentration of IL-1rn, has been associated with coronary atherosclerosis in diabetic patients (63) . However, plasma lipid analysis of IL-1rn -/-xapoE -/-mice revealed that total cholesterol levels were significantly elevated compared with those of the IL-1rn (64) . Therefore, the reduction of IL-1rn that was documented with the microarray analysis of hepatic mRNA of apoE -/-mice that were treated with the adenovirus expressing the dn-c-Jun cannot explain the observed reduction of the plasma cholesterol levels.
Scd-1 is an iron-containing enzyme that catalyzes the rate-limiting step in the synthesis of unsaturated fatty acids and it is expressed abundantly in the liver (33) . It has been reported that Scd-1 -/-mice have very low levels of VLDL and impaired triglyceride and cholesteryl ester biosynthesis (39;40) . Thus, the lipid phenotype described for Scd-1 -/-mice may explain the reduction of plasma cholesterol and triglycerides in apoE -/-mice that were treated with the adenovirus expressing the dn-c-Jun. Although numerous other genes are affected by the treatment of apoE -/-mice with adenovirus expressing the dn-c-Jun (Supplementary Table  1 ) we suggest that the reduction of Scd-1 may be the major event that corrects partially the dyslipidemia in apoE -/-mice following infection with Ad-dn-c-Jun. This interpretation is further supported by restoration of the high cholesterol levels of the apoE -/-mice following simultaneous treatment with adenoviruses expressing dn-c-Jun and Scd-1. The downregulation of Scd-1 may also explain the moderate dyslipidemia that was induced in C57BL/6 mice which were treated with adenovirus expressing the dn-c-Jun as compared to the severe dyslipidemia, which was induced in C57BL/6 mice that were treated with adenovirus expressing the mouse apoE despite the fact that the plasma apoE levels following the two treatments were comparable. The moderate increase of VLDL secretion in C57BL/6 mice treated with the adenovirus expressing the dn-c-Jun can be also attributed to the reduction of Scd-1 that is known to modulate VLDL secretion (39;40) . Further studies are required to elucidate the transcriptional mechanisms by which dn-c-Jun, which lacks a major part of its transactivation domain, induces the expression of the apoE gene. It was shown previously that the exact same molecule (c-Jun lacking amino acids 3-122) is a more potent transactivator as compared with full-length c-Jun in the Sp-1 mediated activation of the human p21WAF1 promoter (65) . It is known that the apoE promoter has three Sp-1 binding sites (66) which may be involved in 8 Sp1-dn-c-Jun interaction that promotes apoE gene transcription. The current study showed that WT c-Jun does not affect apoE gene expression and does not induce dyslipidemia when it is expressed in mice following adenovirus-mediated gene transfer. The direct or indirect role of dn-c-Jun in the downregulation of the Scd-1 gene needs also to be explored. Previous studies indicated that Scd-1 is downregulated by a JNK inhibitor (32) . The observed downregulation of some of the other genes that are affected by the dn-c-Jun may be caused by direct transcriptional repression that results from binding of the dn-c-Jun to AP-1 sites on the promoters of these genes.
Overall, our data indicate that the dn-c-Jun affects two genes that play an important role in the lipid and lipoprotein homeostasis in mice. It upregulates greatly the hepatic expression of the apoE gene and downregulates the expression of the Scd-1 gene (Figure 7 
